Stephen Smith, M.D.
Stephen Smith, M.D.
Associate Member
Clinical Research Division, Fred Hutch
Dr. Stephen Smith is a medical oncologist who cares for patients with lymphoma and other blood disorders. His research focuses on developing new, targeted therapies to treat these diseases.
Other Appointments & Affiliations
Medical Oncologist
Seattle Cancer Care Alliance
Associate Professor
University of Washington
Education
M.D., Keck School of Medicine, University of Southern California, 2002
B.S., Biological Sciences, Stanford University, 1997
Current Projects
NCCN grant, 2014 - 2016 "Oprozomib +/- Rituximab: Response-Adapted Therapy in Untreated Waldenström’s Macroglobulinemia". Collaborative clinical trial with correlative studies in conjunction with the University of Utah Huntsman Cancer Institute
Active Clinical Trials
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
Study Number: 9702
Phase: II
Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
Study Number: 9844
Phase: II
Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Study Number: 9469
Phase: II
A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma
Study Number: 20160991
Phase: I
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Study Number: 20170154
Phase: III
Phase 1/2A Dose Escalation Study in CLL, SLL or NHL
Study Number: 20170188
Phase: I/II
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Study Number: 20170968
Phase: II
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1
Study Number: 20172199
Phase: III
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX)
Study Number: UW17078
Phase: III
Dr. Smith in the News
For the Media
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email media@fredhutch.org or call 206.667.2210